Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 7/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930071 | 0.88 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL30918494 | 0.88 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL6608422 | 0.84 | PDE4B (0.41) | PDE4APDE4BPDE4CPDE4DENPP1 | |
| SCHEMBL6608408 | 0.84 | PDE4A (0.36) | S1PR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9784641 | 0.81 | S1PR1 (0.41) | S1PR1TSHRS1PR3KDM4ECYP3A4 | |
| SCHEMBL22978520 | 0.80 | S1PR1 (0.40) | S1PR1TSHRS1PR3KDM4ECYP3A4 | |
| SCHEMBL4141457 | 0.80 | DPP4 (0.42) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL6612569 | 0.80 | CRHR1 (0.35) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL6610520 | 0.79 | PDE4A (0.38) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL4142722 | 0.79 | PDE4A (0.38) | PDE4APDE4BPDE4CPDE4DMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11628161-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2023-04-18 | — | — | US | disclosed |
| CN-110291065-B | Novel isoindoline derivative, pharmaceutical composition and application thereof | 康朴生物医药技术（上海）有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-11337964-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-11337964-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-20220152002-A1 | ISOINDOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
| US-20220152002-A1 | ISOINDOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
| EP-3590924-B1 | NOVEL ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-3590924-B1 | NOVEL ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-20200061033-A1 | NOVEL ISOINDOLINE DERIVATIVE, A PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| US-20200061033-A1 | NOVEL ISOINDOLINE DERIVATIVE, A PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11337964-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | PDE4A, PDE4B, PDE4C | S1PR1 2733/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20200061033-A1 | NOVEL ISOINDOLINE DERIVATIVE, A PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDE4A, PDE4B, PDE4C | S1PR1 2309/4885PDE4A 1/4885PDE4B 2/4885 |
| US-11628161-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | PDE4A, PDE4B, PDE4C | S1PR1 2733/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20220152002-A1 | ISOINDOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDE4A, PDE4B, PDE4C | S1PR1 2746/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.